CLAIMS

1. A compound of formula (I) or a salt thereof



(I)

in which

X and Y are independently CH or N provided that at least one of X and Y must be CH;

R^1 is a group $C(O)OR^4$ in which R^4 is C_{1-4}alkyl or C_{3-7}cycloalkyl; or

R^1 is a group selected from phenyl, pyridyl, pyrazinyl and pyrimidinyl said groups being optionally substituted by one or two substituents selected from halogen, C_{1-4}alkyl and CN;

R^2 is C_{1-4}alkyl;

R^3 is C_{1-4}alkyl;

R^5 and R^6 are independently C_{1-4}alkyl; or

R^5 and R^6 combine together with the N to which they are attached form a 5 or 6 membered heterocyclyl;

R^7 is absent or is C_{1-4}alkyl;

m is 0, 1 or 2;

n is 1 or 2.

2. A compound or a salt thereof according to claim 1 in which X and Y are both CH.

3. A compound or a salt thereof according to claim 1 in which X is CH and Y is N.

4. A compound or a salt thereof according to any one of claims 1 – 3 in which R^1 is a group ~~$C(O)OR^5$~~ $C(O)OR^4$ in which R^4 is isopropyl.

5. A compound or a salt thereof according to any one of claims 1 – 3 in which R^1 is phenyl or pyridyl optionally substituted by one or two substituents selected from halogen, C_{1-4}alkyl and CN.

6. A compound or a salt thereof according to claim 5 in which R^1 is 4-chlorophenyl or 5-cyanopyridin-2-yl.

7. A compound or a salt thereof according to ony one of claims 1 - 6 in which R^2 is methyl.

8. A compound or a salt thereof according to to ony one of claims 1 - 7 in which R^3 is methyl.

9. A compound or salt thereof according to any one of claims 1 – 8 in which m is 0.

10. A compound or salt thereof according to any one of claims 1 – 9 in which R^5 and R^6 are both methyl.

11. A compound or a salt thereof according to any one of claims 1 – 10 in which R^7 is absent.

12. A compound or a salt thereof according to any one of claims 1 – 11 in which the compound of formula (I) is the (2S, 4R) enantiomer.

13. A compound according to claim 1 which is 2-(dimethylamino)ethyl 4-((2*S*,4*R*)-1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoate or a salt thereof.

14. A compound according to claim 1 which is selected from
2-((4-((2*S*,4*R*)-1-Acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoyl)oxy)-*N*,*N*,*N*-trimethylethanaminium;
3-((4-((2*S*,4*R*)-1-Acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoyl)oxy)-*N*,*N*,*N*-trimethylpropan-1-aminium;
3-(Dimethylamino)propyl 4-((2*S*,4*R*)-1-acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoate;
3-(Dimethylamino)propyl 6-((2*S*,4*R*)-1-acetyl-4-((5-cyanopyridin-2-yl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)nicotinate;
2-(Dimethylamino)ethyl 6-((2*R*,4*R*)-1-acetyl-4-((5-cyanopyridin-2-yl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)nicotinate;
3-(Dimethylamino)propyl 4-((2*S*,4*R*)-1-acetyl-4-((isopropoxycarbonyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoate; and

2-(Dimethylamino)ethyl 4-((2*S*,4*R*)-1-acetyl-4-((isopropoxycarbonyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoate
or a salt thereof.

15. A compound according to any one of claims 1 – 14 or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 15 and one or more pharmaceutically acceptable carriers, diluents or excipients.

17. A combination pharmaceutical product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in 15 together with one or more other therapeutically active agents.

18. A compound or a pharmaceutically acceptable salt thereof as defined in claim 15 for use in therapy.

~~19. A compound or a pharmaceutically acceptable salt thereof as defined in claim 15 for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.~~

~~20~~19. A compound or a pharmaceutically acceptable salt thereof as defined in claim 15 for use in the treatment of a chronic autoimmune and/or inflammatory condition.

~~21~~20. A compound or a pharmaceutically acceptable salt thereof according to claim 15 for use in the treatment of cancer.

~~22. The use of a compound or a pharmaceutically acceptable salt thereof according to claim 15 in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.~~

~~23~~21. The ~~A~~ use of a compound or a pharmaceutically acceptable salt thereof according to claim 15 in the manufacture of a medicament for the treatment of ~~according to claim 22 wherein the disease or condition is~~ a chronic autoimmune and/or inflammatory condition.

~~24~~22. The ~~A~~ use of a compound or a pharmaceutically acceptable salt thereof according to claim 15 in the manufacture of a medicament for the treatment of ~~according to claim 22 wherein the disease or condition is~~ cancer.

~~25. A method for inhibiting a bromodomain which comprises contacting the bromodomain with a compound or a pharmaceutically acceptable salt thereof as defined in claim 15.~~